Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to semaglutide. On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7%
